MedPath

CYCLE PHARMACEUTICALS LTD

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

SFDA:3
FDA:2

Drug Approvals

SAJAZIR

Approval Date
Sep 7, 2023
FDA

TASCENSO ODT

Approval Date
Aug 17, 2023
FDA

Clinical Trials

No trials found

News

FDA Approves First Treatment for Alkaptonuria: Nitisinone Shows Clinical Benefits in Rare Metabolic Disorder

The FDA approved nitisinone (Harliku) as the first and only treatment for alkaptonuria, a rare genetic metabolic disorder affecting 1 in 250,000 to 1 million Americans.

Cycle Pharmaceuticals Launches VENXXIVA for Cystinuria Treatment in the US

Cycle Pharmaceuticals has launched VENXXIVA (tiopronin) Delayed-Release Tablets for treating cystinuria in the US, partnering with Torrent Pharma and Vanscoy Rare Pharmacy for distribution.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.